Chauhan, Pradeep S.
Shiang, Alexander
Alahi, Irfan
Sundby, R. Taylor http://orcid.org/0000-0001-8485-0026
Feng, Wenjia http://orcid.org/0000-0002-6320-3927
Gungoren, Bilge http://orcid.org/0000-0001-8988-5594
Nawaf, Cayce
Chen, Kevin
Babbra, Ramandeep K. http://orcid.org/0000-0002-6244-5107
Harris, Peter K.
Qaium, Faridi
Hatscher, Casey
Antiporda, Anna
Brunt, Lindsey
Mayer, Lindsey R.
Shern, Jack F.
Baumann, Brian C.
Kim, Eric H.
Reimers, Melissa A.
Smith, Zachary L.
Chaudhuri, Aadel A. http://orcid.org/0000-0003-3115-3061
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA238711)
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (UL1TR002345)
Article History
Received: 31 August 2022
Accepted: 21 December 2022
First Online: 19 January 2023
Competing interests
: P.S.C., I.A., R.T.S., K.C., Z.L.S., and A.A.C. have patent filings related to cancer biomarkers. F.Q. has stock options in Centene, Gilead, and Horizon Therapeutics. B.C.B. discloses honoraria from Mevion Medical Systems and consulting work for Regeneron/Sanofi, outside of the submitted work. Z.L.S. serves as a consultant/advisor for Photocure, outside the submitted work. A.A.C. has licensed technology to Droplet Biosciences, Tempus Labs, and Biocognitive Labs. A.A.C. has served as a consultant/advisor to Roche, Tempus, Illumina, Geneoscopy, NuProbe, Daiichi Sankyo, AstraZeneca, AlphaSights, DeciBio, and Guidepoint. A.A.C. has received honoraria from Roche, Foundation Medicine, and Dava Oncology. A.A.C. has stock options in Geneoscopy, research support from Roche, Illumina and Tempus Labs, and ownership interests in Droplet Biosciences and LiquidCell Dx. The remaining authors declare no competing interests.